The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1368
Levofloxacin Revisited
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

A Medical Letter reader has asked us to review the safety of the fluoroquinolone antibiotic levofloxacin (Levaquin – Ortho-McNeil-Janssen), which has just been approved for generic use by the FDA and has been at the center of some recent lawsuits regarding the adequacy of its safety warnings.

ACTIVITY — The fluoroquinolones are synthetic antibacterial agents with activity against many gram-positive and gram-negative organisms. Levofloxacin, like moxifloxacin (Avelox) and gemifloxacin (Factive), is more active than ciprofloxacin (Cipro, and others) or ofloxacin (Floxin, and others) against gram-positive organisms such as Streptococcus pneumoniae, including strains highly resistant to penicillin. Like other fluoroquinolones, it is active against Legionella pneumophila, Chlamydophila pneumoniae and Mycoplasma pneumoniae. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Levofloxacin Revisited
Article code: 1368c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian